Recent Updates — INDP
Indaptus Therapeutics, Inc. completed a private placement of 20,338,974 shares of common stock to purchasers party to the Stock Purchase Agreement dated September 8, 2026. The company received aggregate gross proceeds of approximately $24.0 million before deducting offering expenses. This closing follows an extension of the outside date from September 29, 2026, to October 16, 2026. Indaptus Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.
Indaptus Therapeutics extended the outside date for its previously announced $24.0 million private placement of common stock from September 29, 2026, to October 16, 2026. The company and purchasers agreed to defer and coordinate the closing until conditions are satisfied or waived. Indaptus Therapeutics operates in the biotechnology industry.
On September 8, 2026, Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement to issue and sell 20,338,974 shares of common stock in a private placement for aggregate gross proceeds of approximately $24.0 million. The purchase price per share equals the Nasdaq Minimum Price plus $0.015, where the Nasdaq Minimum Price is the lower of the prior day's closing price or the five-day average closing price. Net proceeds are intended for working capital, research and development, and general corporate purposes, including early-stage evaluation of a potential neurotechnology device for sleep-related conditions with a view toward future FDA submission. The closing is subject to customary conditions and must occur within fifteen business days following September 8, 2026. Indaptus Therapeutics operates in the biotechnology industry, focusing on developing treatments for neurological disorders.
Indaptus Therapeutics, Inc. entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC on August 28, 2026. This agreement supersedes the prior June 1, 2022 arrangement and authorizes the company to sell up to $100,000,000 in shares of common stock through an at-the-market program. The company will pay Wainwright a placement fee equal to 3.0% of the gross sales price for shares sold as agent. This filing updates disclosure regarding dilution in connection with a prospectus supplement filed on August 31, 2026. Indaptus Therapeutics operates in the biotechnology industry, focusing on the development of therapies.
On September 2, 2026, Tim Ruan resigned from the Board of Directors of Indaptus Therapeutics, Inc., effective immediately. The company stated that his departure was not due to any disagreement regarding operations, policies, or practices. This governance change is material as it alters the composition of the board. Indaptus Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.
Indaptus Therapeutics, Inc. entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC on August 28, 2026. This agreement supersedes the prior June 1, 2022 arrangement and authorizes the company to sell up to $100,000,000 in shares of common stock through an at-the-market program. The filing includes a prospectus supplement dated August 31, 2026, linked to an effective Form S-3 shelf registration statement. Wainwright acts as sales agent for a 3.0% placement fee, with no obligation for the company to sell shares or for the agent to purchase them on a principal basis. Indaptus Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic diseases.